The use of the palliative prognostic score in patients with diagnoses other than cancer

Glare, Paul; Eychmueller, Steffen; Virik, Kiran

doi:10.1016/s0885-3924(03)00335-x

Cited by 33 publications

(21 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…These two factors are incorporated into the PaP score, which was originally built for a cancer population (excluding hematological and kidney cancers) undergoing palliative care [19,20]. Other studies have since highlighted its efficacy in all cancer types and also in non-cancer populations [44, 45,48]. A further criticism is that the score requires a blood sample to be taken.…”

Section: Discussionmentioning

confidence: 99%

Prospective Comparison of Prognostic Scores in Palliative Care Cancer Populations

Maltoni

Scarpi²,

Pittureri³

et al. 2012

The Oncologist

123

113

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Prospective Comparison of Prognostic Scores in Palliative Care Cancer Populations

Maltoni

Scarpi²,

Pittureri³

et al. 2012

The Oncologist

123

113

View full text Add to dashboard Cite

“…Total palliative prognostic scores can range between 0 and 17.5 and define three prognostic categories representing different probabilities of surviving 30 days (<30%, 30-70%, and >70%). The palliative prognostic score has been subsequently validated in several clinical studies 33–37. One of its drawbacks is the heavy weighting that is attributed to the clinician's prediction of survival; the partial score for the clinician's prediction can represent 8.8/17.5 (49%) of the total score.…”

Section: Discussionmentioning

confidence: 99%

Development of Prognosis in Palliative care Study (PiPS) predictor models to improve prognostication in advanced cancer: prospective cohort study

Gwilliam

Keeley

Todd

et al. 2012

BMJ Support Palliat Care

View full text Add to dashboard Cite

Objective To develop a novel prognostic indicator for use in patients with advanced cancer that is significantly better than clinicians' estimates of survival.Design Prospective multicentre observational cohort study.Setting 18 palliative care services in the UK (including hospices, hospital support teams, and community teams).Participants 1018 patients with locally advanced or metastatic cancer, no longer being treated for cancer, and recently referred to palliative care services. Main outcome measuresPerformance of a composite model to predict whether patients were likely to survive for "days" (0-13 days), "weeks" (14-55 days), or "months+" (>55 days), compared with actual survival and clinicians' predictions.Results On multivariate analysis, 11 core variables (pulse rate, general health status, mental test score, performance status, presence of anorexia, presence of any site of metastatic disease, presence of liver metastases, C reactive protein, white blood count, platelet count, and urea) independently predicted both two week and two month survival. Four variables had prognostic significance only for two week survival (dyspnoea, dysphagia, bone metastases, and alanine transaminase), and eight variables had prognostic significance only for two month survival (primary breast cancer, male genital cancer, tiredness, loss of weight, lymphocyte count, neutrophil count, alkaline phosphatase, and albumin). Separate prognostic models were created for patients without (PiPS-A) or with (PiPS-B) blood results. The area under the curve for all models varied between 0.79 and 0.86. Absolute agreement between actual survival and PiPS predictions was 57.3% (after correction for over-optimism). The median survival across the PiPS-A categories was 5, 33, and 92 days and survival across PiPS-B categories was 7, 32, and 100.5 days. All models performed as well as, or better than, clinicians' estimates of survival. ConclusionsIn patients with advanced cancer no longer being treated, a combination of clinical and laboratory variables can reliably predict two week and two month survival. IntroductionPatients with advanced cancer and their carers often wish to know how long they have left to live. 1 2 Accurate prognostic information can allow patients adequate time to prepare for their impending death. 3 Qualitative studies show that patients in palliative care want to be given honest and accurate prognostic information but that this information needs to be shared sensitively and in a way that respects patients' desire to maintain hope. 4 5 Prognostic information is also important for clinicians. Realistic survival estimates can inform decisions about the appropriateness of medical interventions and the timing of referral to specialist palliative care services or admission to a hospice. Clinicians' predictions are routinely used to prioritise patients who are suitable for inclusion in programmes such as the Gold Standards Framework, 6 to determine which patients RESEARCHare suitable for "fast-tracking" arrangements for ...

show abstract

“…25 The Palliative Prognostic Score, a tool to stratify patients into groups based on predicted 30-day survival, also uses the presence of dyspnea as an integral part of its survival prediction. 26 …”

Section: Burden and Consequences In Advanced Diseasementioning

confidence: 99%

Dyspnea Review for the Palliative Care Professional: Assessment, Burdens, and Etiologies

Kamal

Maguire

Wheeler

et al. 2011

Journal of Palliative Medicine

View full text Add to dashboard Cite

show abstract

The use of the palliative prognostic score in patients with diagnoses other than cancer

Cited by 33 publications

References 9 publications

Prospective Comparison of Prognostic Scores in Palliative Care Cancer Populations

Prospective Comparison of Prognostic Scores in Palliative Care Cancer Populations

Development of Prognosis in Palliative care Study (PiPS) predictor models to improve prognostication in advanced cancer: prospective cohort study

Dyspnea Review for the Palliative Care Professional: Assessment, Burdens, and Etiologies

Contact Info

Product

Resources

About